Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration

• Status: Unknown status
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the investigators study is to look at the visual outcomes of Ranibizumab injections in combination with photodynamic therapy for the treatment of neovascular age-related macular degeneration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: McGill University Health Center; McGill University Health Centre/Research Institute of the McGill University Health Centre
• Treatments: Ranibizumab; Verteporfin

Criteria

Inclusion Criteria:

• diagnosed with any subtype of primary subfoveal or juxtafoveal choroidal neovascularization

• must be 50 years of age or older

• have a lesion whose total size is no more than 5400micrometres in greatest linear dimension in the study eye

• CNV that is more than 50% obscured by blood

• have best corrected visual acuity of 20/50-20/320 (Snellen equivalent)

• have been assessed with the use of early treatment diabetic retinopathy study charts

Exclusion Criteria:

• previous treatment (including verteporfin therapy) that could compromise an assessment of the study treatment

• any permanent structural damage to the central fovea